SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes
**Background:** Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because ma